Lucence strategic collaboration
Revolutionizing liquid biopsy
LiquidHALLMARK® moves beyond traditional ctDNA-only approaches by analyzing both ctDNA and ctRNA, increasing clinically actionable findings by over 15%.
Global reach, local expertise
This strategic collaboration combines Mayo Clinic Laboratories’ diagnostic leadership with Lucence’s pioneering technology to make advanced cancer testing accessible worldwide.
Actionable insights for care
LiquidHALLMARK® delivers comprehensive genomic profiles, including targeted therapies and clinical trial options, empowering physicians to personalize treatment plans.
“Incorporating LiquidHALLMARK® into our testing portfolio supports our commitment to providing comprehensive, innovative cancer diagnostics for patients worldwide.”
William Morice II, M.D., Ph.D., President and CEO, Mayo Clinic Laboratories
The latest
LiquidHALLMARK combines DNA and RNA for more accurate cancer profiling, helping patients access lifesaving therapies.
Join us for a webinar exploring how LiquidHALLMARK®, a cutting-edge liquid biopsy test, is transforming cancer care.
In the first quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests.
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.
Mayo Clinic Laboratories and Lucence are expanding access to advanced cancer testing worldwide with LiquidHALLMARK®, a next-generation liquid biopsy that provides actionable genomic insights. This collaboration empowers physicians to deliver personalized care and improve patient outcomes.